MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-03-2026
Intuitive Surgical Income Statement 2011-2026 | ISRG
Annual Income Statement Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
171 B | 203 B | 133 B | 87 B | 103 B | 86.2 B | 65.9 B | 57.8 B | 47.8 B | 26.4 B | 20.1 B | 18.2 B | 16.7 B | 22.8 B | 17.9 B |
Shares |
357 M | 355 M | 351 M | 356 M | 356 M | 351 M | 115 M | 114 M | 112 M | 115 M | 111 M | 111 M | 120 M | 119 M | 118 M |
Historical Prices |
479 | 572 | 379 | 245 | 290 | 246 | 178 | 183 | 142 | 81.9 | 62.6 | 55.6 | 49.4 | 56.7 | 56.8 |
Net Income |
2.86 B | 2.32 B | 1.8 B | 1.32 B | 1.7 B | 1.06 B | 1.38 B | 1.13 B | 660 M | 736 M | 589 M | 419 M | 671 M | 657 M | 495 M |
Revenue |
10.1 B | 8.35 B | 7.12 B | 6.22 B | 5.71 B | 4.36 B | 4.48 B | 3.72 B | 3.13 B | 2.7 B | 2.38 B | 2.13 B | 2.27 B | 2.18 B | 1.76 B |
Cost of Revenue |
3.42 B | 2.72 B | 2.39 B | 2.03 B | 1.75 B | 1.5 B | 1.37 B | 1.12 B | 935 M | 814 M | 806 M | 718 M | 671 M | 608 M | 484 M |
Gross Profit |
6.64 B | 5.63 B | 4.73 B | 4.2 B | 3.96 B | 2.86 B | 3.11 B | 2.6 B | 2.19 B | 1.89 B | 1.58 B | 1.41 B | 1.59 B | 1.57 B | 1.27 B |
Operating Income |
2.95 B | 2.35 B | 1.77 B | 1.58 B | 1.82 B | 1.05 B | 1.37 B | 1.2 B | 1.06 B | 950 M | 740 M | 545 M | 852 M | 878 M | 695 M |
EBITDA |
3.55 B | 2.79 B | 2.15 B | 1.9 B | 2.1 B | 1.27 B | 1.58 B | 1.32 B | 1.15 B | 1.04 B | 830 M | 619 M | 920 M | 936 M | 741 M |
Operating Expenses |
3.7 B | 3.29 B | 2.96 B | 2.62 B | 2.14 B | 1.81 B | 1.74 B | 1.4 B | 1.14 B | 945 M | 838 M | 869 M | 742 M | 692 M | 579 M |
General and Administrative Expenses |
2.38 B | 2.14 B | 1.96 B | 1.74 B | 1.47 B | 1.22 B | 1.18 B | 987 M | 811 M | 705 M | 640 M | 691 M | 574 M | 522 M | 439 M |
All numbers in USD currency
Quarterly Income Statement Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
357 M | 358 M | 358 M | 357 M | 356 M | 355 M | 354 M | 352 M | 352 M | 351 M | 350 M | 350 M | 355 M | - | 358 M | 358 M | 357 M | 119 M | 354 M | 353 M | 352 M | 117 M | 116 M | 116 M | 115 M | 115 M | 115 M | 114 M | 114 M | 114 M | 113 M | 112 M | 112 M | 111 M | 112 M | 116 M | 116 M | 38.3 M | 37.7 M | 37.4 M | 37.3 M | 36.9 M | 36.7 M | 36.6 M | 36.1 M | 36.9 M | 38.3 M | 38.2 M | 38.6 M | 39.9 M | 40.3 M | 40.2 M | 39.9 M | 39.9 M | 39.5 M | 39.3 M | 39.1 M | 39.2 M | 39.1 M |
Net Income |
704 M | 658 M | 698 M | - | 565 M | 527 M | 545 M | - | 416 M | 421 M | 355 M | - | 324 M | - | 366 M | 381 M | 380 M | 517 M | 426 M | 365 M | 314 M | 68 M | 314 M | 358 M | 397 M | 318 M | 306 M | 292 M | 292 M | 255 M | 288 M | -31.5 M | 299 M | 223 M | 181 M | 204 M | 211 M | 184 M | 136 M | 190 M | 167 M | 134 M | 97 M | 147 M | 124 M | 104 M | 44.3 M | 166 M | 157 M | 159 M | 189 M | 175 M | 183 M | 155 M | 144 M | 151 M | 122 M | 117 M | 104 M |
Revenue |
2.51 B | 2.44 B | 2.25 B | - | 2.04 B | 2.01 B | 1.89 B | - | 1.74 B | 1.76 B | 1.7 B | - | 1.56 B | - | 1.49 B | 1.55 B | 1.4 B | 1.46 B | 1.29 B | 1.33 B | 1.08 B | 852 M | 1.1 B | 1.28 B | 1.13 B | 1.1 B | 974 M | 1.05 B | 921 M | 909 M | 848 M | 892 M | 806 M | 759 M | 680 M | 757 M | 683 M | 670 M | 594 M | 676 M | 590 M | 586 M | 532 M | 605 M | 550 M | 512 M | 465 M | 576 M | 499 M | 578 M | 611 M | 609 M | 538 M | 536 M | 495 M | 497 M | 447 M | 426 M | 388 M |
Cost of Revenue |
843 M | 822 M | 796 M | - | 664 M | 637 M | 645 M | - | 576 M | 584 M | 583 M | - | 505 M | - | 478 M | - | 432 M | 440 M | 390 M | - | 353 M | 349 M | 361 M | - | 343 M | 340 M | 304 M | - | 279 M | 277 M | 254 M | - | 239 M | 229 M | 210 M | - | 196 M | 199 M | 190 M | - | 194 M | 200 M | 195 M | - | 190 M | 168 M | 149 M | - | 142 M | 173 M | 177 M | - | 148 M | 150 M | 139 M | - | 121 M | 119 M | 109 M |
Gross Profit |
1.66 B | 1.62 B | 1.46 B | - | 1.37 B | 1.37 B | 1.25 B | - | 1.17 B | 1.17 B | 1.11 B | - | 1.05 B | - | 1.01 B | 1.06 B | 971 M | 1.02 B | 903 M | 896 M | 724 M | 503 M | 738 M | 896 M | 786 M | 759 M | 670 M | 736 M | 642 M | 632 M | 594 M | 634 M | 568 M | 530 M | 470 M | 527 M | 487 M | 471 M | 405 M | 459 M | 396 M | 386 M | 337 M | 393 M | 361 M | 344 M | 315 M | 398 M | 357 M | 405 M | 434 M | 438 M | 390 M | 386 M | 356 M | 363 M | 326 M | 307 M | 279 M |
Operating Income |
760 M | 743 M | 578 M | - | 577 M | 567 M | 469 M | - | 466 M | 463 M | 388 M | - | 399 M | - | 408 M | - | 443 M | 511 M | 417 M | - | 270 M | 80.6 M | 283 M | - | 366 M | 359 M | 252 M | - | 313 M | 277 M | 277 M | - | 281 M | 260 M | 193 M | - | 256 M | 245 M | 179 M | - | 190 M | 174 M | 130 M | - | 159 M | 143 M | 56.6 M | - | 174 M | 218 M | 251 M | - | 211 M | 225 M | 193 M | - | 179 M | 168 M | 148 M |
EBITDA |
763 M | 747 M | 582 M | - | 581 M | 572 M | 474 M | - | 471 M | 468 M | 393 M | - | 407 M | - | 414 M | - | 449 M | 519 M | 482 M | - | 430 M | 183 M | 334 M | - | 474 M | 427 M | 284 M | - | 390 M | 327 M | 300 M | - | 342 M | 300 M | 212 M | - | 310 M | 281 M | 197 M | - | 236 M | 203 M | 144 M | - | 197 M | 168 M | 68.9 M | - | 207 M | 240 M | 262 M | - | 237 M | 240 M | 201 M | - | 200 M | 182 M | 155 M |
Operating Expenses |
903 M | 874 M | 880 M | - | 797 M | 805 M | 776 M | - | 701 M | 709 M | 725 M | - | 653 M | - | 602 M | - | 529 M | 512 M | 486 M | - | 454 M | 422 M | 455 M | - | 420 M | 400 M | 417 M | - | 329 M | 355 M | 317 M | - | 288 M | 270 M | 276 M | - | 231 M | 226 M | 226 M | - | 206 M | 213 M | 206 M | - | 202 M | 201 M | 259 M | - | 182 M | 187 M | 183 M | - | 179 M | 161 M | 163 M | - | 147 M | 138 M | 130 M |
General and Administrative Expenses |
573 M | 561 M | 563 M | - | 511 M | 525 M | 492 M | - | 452 M | 464 M | 480 M | - | 436 M | - | 391 M | - | 363 M | 350 M | 326 M | - | 299 M | 279 M | 308 M | - | 284 M | 279 M | 273 M | - | 221 M | 260 M | 222 M | - | 204 M | 186 M | 203 M | - | 168 M | 171 M | 173 M | - | 155 M | 163 M | 162 M | - | 154 M | 161 M | 216 M | - | 139 M | 146 M | 142 M | - | 129 M | 121 M | 124 M | - | 111 M | 106 M | 99.1 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Intuitive Surgical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B |  USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
AtriCure
ATRC
|
$ 31.07 | -1.26 % | $ 1.48 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
The Cooper Companies
COO
|
$ 81.93 | -1.73 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 84.0 | 1.13 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.9 | 9.0 % | $ 26.4 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
$ 19.1 | 0.45 % | $ 9.8 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 115.62 | -1.86 % | $ 5.6 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 64.55 | -1.59 % | $ 3.25 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.57 | 4.25 % | $ 198 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 127.87 | 1.61 % | $ 4.09 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.88 | 2.2 % | $ 223 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.58 | 2.14 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 106.91 | -0.87 % | $ 2.42 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 171.22 | -1.8 % | $ 49.3 B | USA |
 |
Masimo Corporation
MASI
|
$ 175.43 | 0.04 % | $ 9.35 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.47 | 3.28 % | $ 25.2 M |  Israel |
 |
AngioDynamics
ANGO
|
$ 10.98 | -0.54 % | $ 449 M | USA |
 |
BioLife Solutions
BLFS
|
$ 20.59 | 2.06 % | $ 949 M | USA |
 |
Nephros
NEPH
|
$ 3.92 | 1.29 % | $ 40.7 M | USA |
 |
electroCore
ECOR
|
$ 7.9 | 3.81 % | $ 43.6 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 28.51 | -0.52 % | $ 4.79 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.68 | -3.05 % | $ 20.4 M | USA |
 |
ICU Medical
ICUI
|
$ 142.18 | -0.34 % | $ 3.5 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 18.29 | 1.89 % | $ 1.23 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 74.53 | -0.43 % | $ 4.41 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Repligen Corporation
RGEN
|
$ 126.05 | 2.43 % | $ 7.02 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | 0.67 % | $ 223 M | USA |
 |
ResMed
RMD
|
$ 258.94 | 0.22 % | $ 37.8 B | USA |
 |
Pro-Dex
PDEX
|
$ 48.51 | 2.1 % | $ 159 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.17 | 1.32 % | $ 950 M | USA |
 |
STERIS plc
STE
|
$ 244.67 | 0.62 % | $ 24.1 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 119.41 | -2.24 % | $ 5.33 B | USA |
 |
Stereotaxis
STXS
|
$ 2.22 | 3.74 % | $ 179 M | USA |
 |
Utah Medical Products
UTMD
|
$ 67.17 | 0.99 % | $ 244 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 250.46 | -0.3 % | $ 18.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 13.47 | 1.24 % | $ 2.69 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 2.33 % | $ 23.1 M | USA |